Amgen's (AMGN +2% premarket) Phase III trial of its under-the-skin osteoporosis drug denosumab...Sep. 21, 2009 9:17 AM ETAmgen Inc. (AMGN) StockAMGN, NVSBy: Eli Hoffmann, SA News Editor Amgen's (AMGN +2% premarket) Phase III trial of its under-the-skin osteoporosis drug denosumab delayed skeletal-related events (fractures etc.) for 20.6 months vs. 16.3 months for intravenously-injected rival Zometa (NVS -1%). (PR) Recommended For YouMore Trending NewsSee More »About AMGN StockSymbolLast Price% Chg1D5D1M6M1Y5Y10YMarket CapPEYield (TTM)Rev Growth (YoY)Prev. CloseCompare to PeersRelated StocksSymbolLast Price% ChgAMGN--Amgen Inc.Trending AnalysisTrending News